Assessment of Mitochondrial Function Following Long-Term Treatment of Human Bronchial Epithelial Cells with Total Particulate Matter from a candidate Modified-Risk Tobacco Product versus Cigarettes
Van der Toorn, M.; Malińska, D.; Szymanski, J.; Walczak, J.; Prill, M.; Drabik, K.; Michalska, B.; Wojtala, A.; Patalas-Krawczyk, P.; Partyka, M.; Johne, S. Johne.; Sewer, A.; Guedj, E.; Luettich, K.; Peitsch, M. C.; Hoeng, J.; Wieckowski, M.; Szczepanowska, J.; Duszynski, J.
Aug 24, 2017
Tenth World Congress - Alternatives and Animal Use in the Life Sciences
PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.
Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.